| Study name |
Setting |
Treatment |
RR (CR+PR) (%) |
mPFS
(months) |
mOS
(months) |
BOND
(phase II) |
IRI failure
(n=329) |
IRI+C-mab
C-mab |
22.9 (p=0.007)
10.8 |
4.1 (p<0.001)
1.5 |
8.6
6.9 |
NCIC CO.17
(phase III) |
5-FU, IRI, OX failure
(n=572) |
C-mab+BSC
BSC |
8.0 (p<0.001)
0 |
1.9 (p<0.0001)
1.8. |
6.1 (p=0.005)
4.6 |
CRYSTAL
(phase III) |
1st-line
(n=1217) |
FOLFIRI+C-mab
FOLFIRI |
46.9 (p<0.004)
38.7 |
8.9 (p<0.048)
8.0 |
19.9
18.6 |
OPUS
(phase II) |
1st-line
(n=337) |
FOLFOX+C-mab
FOLFOX |
46
36 |
7.2
7.2 |
N.R.
N.R. |
RR: response rate, CR: complete response, PR: partial response, mPFS: median progression free survival, mOS: median overall survival, N.R.: not reported. C-mab:
cetuximab, IRI: irinotecan, OX: oxaliplatine, FOLFIRI: irinotecan/5-FU/leucovorin, FOLFOX: oxaliplatine/5-FU/leucovorin |
